Lawmakers are currently considering legislation to reauthorize FDA user fees. The FDA largely relies on user fees to operate and review innovative drugs, biologics, and devices. Not only does this legislation provide critical funding for FDA to quickly review products, but the user fee agreements also provide patients and patient organizations with opportunities to participate in FDA initiatives and therapeutic review.
We need your help! Please join us and add your organization’s name to our new sign-on letter. NORD is teaming up with the National Health Council on this effort. Together, let’s tell Congress they must not jeopardize this critical legislation with political fights. Millions of people with rare and chronic diseases and disabilities rely on FDA to access innovative, safe, and effective treatments.
Deadline: We ask that all signatures be submitted by April 20.
Contact: If you have questions about this effort, please contact Paul Melmeyer with NORD ([email protected]) or Eric Gascho with the NHC ([email protected]).
Read all of NORD’s recent policy statements here.
